diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
index 8958d7930..f01f4af30 100644
--- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md	
+++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md	
@@ -49,10 +49,16 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
 
 
 ### Additional Evidence (challenge)
-*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
 
 At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
+
+Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits (T2D, obesity, MASH) are comprehensively accounted for. T2D-related savings ($892M) exceed obesity-related costs ($205M). This suggests the 'inflationary through 2035' claim requires scope qualification: system-level vs. risk-bearing payer economics diverge when downstream savings accrue to the same entity paying for treatment.
+
 ---
 
 Relevant Notes:
diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
index 764c971a2..5c07d399b 100644
--- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
+++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md
@@ -50,10 +50,16 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-01-select-cost-effectiveness-analysis-obesity-cvd]] | Added: 2026-03-16*
+*Source: 2025-01-01-select-cost-effectiveness-analysis-obesity-cvd | Added: 2026-03-16*
 
 Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
+
+Quantified multi-organ benefits in Medicare population: 38,950 CV events avoided, 6,180 deaths prevented, with per-subject savings of $14,431 (T2D), $2,074 (CKD), and $1,512 (CV events) over 10 years. MASH savings are modest ($28M total) despite clinical efficacy, suggesting MASH treatment costs don't accumulate enough in the 10-year window to produce large offsets.
+
 ---
 
 Relevant Notes:
diff --git a/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md b/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md
index a23f37e51..5d8a4f949 100644
--- a/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md	
+++ b/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md	
@@ -33,10 +33,16 @@ The composition of spending shifts dramatically: less on chronic disease managem
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-23-cbo-medicare-trust-fund-2040-insolvency]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2026-02-23-cbo-medicare-trust-fund-2040-insolvency | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 (extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
+
+The Medicare semaglutide case demonstrates a boundary condition: when a single risk-bearing payer captures multi-indication downstream savings, prevention can be cost-saving rather than inflationary. This suggests the cost curve trajectory depends critically on payment structure—capitated/risk-bearing arrangements may bend differently than fee-for-service fragmented systems.
+
 ---
 
 Relevant Notes:
diff --git a/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json b/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json
new file mode 100644
index 000000000..21ac0e297
--- /dev/null
+++ b/inbox/archive/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json
@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}
\ No newline at end of file
diff --git a/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md b/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md
index e5b44f11a..396008b01 100644
--- a/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md
+++ b/inbox/archive/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md
@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: [internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,14 @@ Key findings:
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
 EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
+
+
+## Key Facts
+- Medicare semaglutide modeling projects $715M net savings over 10 years (range: $412M to $1.04B)
+- 38,950 cardiovascular events avoided over 10 years in Medicare population
+- 6,180 deaths avoided (CV + CKD/MASH progression)
+- Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
+- Average per-subject lifetime treatment costs: $47,353
+- T2D-related Medicare savings: ~$892M over 10 years
+- Obesity-related Medicare costs: ~$205M over 10 years
+- MASH-related Medicare savings: ~$28M over 10 years